FDA Discussion Update on Histogenics
In the HSGX longs community (i.e. Stocktwits) it is expected that there will be another update by the company CEO Adam Grizley by the end of year. As there haven't been any updates on the FDA discussions concerning BLA submission since 11-29-2018. The product NeoCart failed phase 3 because it didn't meet Histogenics criteria, not the FDA's. While the FDA continue to go over the data Histogenics stands by with a steady gain in SP.
Go long, go strong, or go home. I'm in for the ride through 2019. Maybe compounding in the dips along the way. Gonna be a great ride!
Go long, go strong, or go home. I'm in for the ride through 2019. Maybe compounding in the dips along the way. Gonna be a great ride!
Clause de non-responsabilité
Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.